论文部分内容阅读
目的通过恩度联合化疗治疗晚期非小细胞肺癌的临床分析,旨在为提高临床化疗治疗有效率、延长患者生命提供一定的理论研究依据。方法选择2016年初至2017年初期间本院纳入的16例晚期非小细胞肺癌患者,按照化疗治疗的临床方案进行针对性分组,8例联合化疗组和8例单纯化疗组两组。单纯化疗组患者均给予单纯化疗方案治疗,而联合化疗组患者给与恩度联合化疗方案治疗,对比两组晚期非小细胞肺癌患者的近期治疗总有效率及不良性反应发生率。结果联合化疗组患者的近期治疗总有效率为87.50%(7/8),显著高于单纯化疗组的50%(4/8),差异分析统计学意义鲜明(P<0.05);同时,联合化疗组患者的不良性反应发生率为25%(2/8,呕吐2例),与单纯化疗组的50%(4/8,呕吐2例、头痛乏力2例),差异统计学意义显见(P<0.05)。结论恩度联合化疗方案对晚期非小细胞肺癌的近期治疗总有效率显著提高于单纯化疗方案,且可拖延疾病的发展,减少并减缓不良性反应的发生及程度,是一种较安全、较高效的抗癌方式。
Objective To evaluate the clinical efficacy of entecavir combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). The aim is to provide some theoretical basis for improving the efficiency of clinical chemotherapy and prolonging the life of patients. Methods Sixteen patients with advanced non-small cell lung cancer admitted to our hospital from the beginning of 2016 to the beginning of 2017 were divided into two groups according to the clinical regimen of chemotherapy, 8 combined chemotherapy and 8 chemotherapy alone. Patients in the chemotherapy alone group were treated with chemotherapy alone, while patients in the combined chemotherapy group were treated with Endo combined with chemotherapy regimen. The total effective rate and incidence of adverse reactions in the two groups of patients with advanced non-small cell lung cancer were compared. Results The total effective rate was 87.50% (7/8) in the combined chemotherapy group, which was significantly higher than that in the chemotherapy group (50%, 4/8). The difference was statistically significant (P <0.05) The incidence of adverse reactions in the chemotherapy group was 25% (2/8, 2 cases of vomiting), 50% (4/8, vomiting in 2 cases and 2 cases of headache fatigue) in the chemotherapy group, the difference was statistically significant P <0.05). Conclusion The combination of Endostar combined chemotherapy for advanced non-small cell lung cancer in the recent treatment of the total effective rate was significantly higher than the chemotherapy alone, and can delay the development of the disease, reduce and slow the occurrence and extent of adverse reactions is a more secure Efficient anti-cancer approach.